Schnitzer Steel Industries, Inc. (SCHN) Reaches $35.68 After 6.00% Up Move; 9 Analysts Covering Akebia Therapeutics, Inc. (AKBA)

February 16, 2018 - By Richard Conner

Among 11 analysts covering Akebia Therapeutics Inc (NASDAQ:AKBA), 9 have Buy rating, 0 Sell and 2 Hold. Therefore 82% are positive. Akebia Therapeutics Inc had 24 analyst reports since August 13, 2015 according to SRatingsIntel. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, December 15. The stock of Akebia Therapeutics, Inc. (NASDAQ:AKBA) earned “Buy” rating by H.C. Wainwright on Monday, July 10. The stock of Akebia Therapeutics, Inc. (NASDAQ:AKBA) earned “Buy” rating by H.C. Wainwright on Wednesday, August 9. On Tuesday, June 6 the stock rating was maintained by H.C. Wainwright with “Buy”. As per Tuesday, November 15, the company rating was initiated by Aegis Capital. The rating was maintained by H.C. Wainwright on Tuesday, March 15 with “Buy”. On Thursday, January 21 the stock rating was initiated by Credit Suisse with “Neutral”. The stock of Akebia Therapeutics, Inc. (NASDAQ:AKBA) earned “Buy” rating by Aegis Capital on Monday, June 5. The firm has “Buy” rating given on Thursday, December 7 by BTIG Research. The stock has “Hold” rating by RBC Capital Markets on Thursday, November 2. See Akebia Therapeutics, Inc. (NASDAQ:AKBA) latest ratings:

18/12/2017 Broker: Piper Jaffray Rating: Buy New Target: $26.0 Initiate
07/12/2017 Broker: BTIG Research Rating: Buy New Target: $30.0 Initiate
02/11/2017 Broker: RBC Capital Markets Rating: Hold New Target: $17.0 Maintain
04/10/2017 Broker: Mizuho Rating: Buy New Target: $24.0 Initiate
15/09/2017 Broker: RBC Capital Markets Rating: Sector Perform New Target: $17 Initiates Coverage On

The stock of Schnitzer Steel Industries, Inc. (NASDAQ:SCHN) is a huge mover today! The stock increased 2.37% or $0.825 during the last trading session, reaching $35.675. About 137,205 shares traded. Schnitzer Steel Industries, Inc. (NASDAQ:SCHN) has risen 21.74% since February 16, 2017 and is uptrending. It has outperformed by 5.04% the S&P500.The move comes after 7 months positive chart setup for the $940.80 million company. It was reported on Feb, 16 by Barchart.com. We have $37.82 PT which if reached, will make NASDAQ:SCHN worth $56.45 million more.

Schnitzer Steel Industries, Inc. recycles ferrous and nonferrous scrap metals; and makes finished steel products worldwide. The company has market cap of $940.80 million. It operates through two divisions, Auto and Metals Recycling and Steel Manufacturing Business (SMB). It has a 15.78 P/E ratio. The AMR segment buys, collects, processes, recycles, sells, and brokers scrap metals, as well as processes mixed and large pieces of scrap metal into smaller pieces by crushing, torching, shearing, shredding, and sorting.

Among 4 analysts covering Schnitzer Steel Industries (NASDAQ:SCHN), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Schnitzer Steel Industries has $29 highest and $17 lowest target. $24’s average target is -32.73% below currents $35.675 stock price. Schnitzer Steel Industries had 6 analyst reports since August 12, 2015 according to SRatingsIntel. The rating was downgraded by Zacks on Wednesday, August 12 to “Buy”. As per Wednesday, October 11, the company rating was maintained by KeyBanc Capital Markets. Morgan Stanley maintained Schnitzer Steel Industries, Inc. (NASDAQ:SCHN) on Tuesday, October 31 with “Equal-Weight” rating. The rating was upgraded by Morgan Stanley to “Equal-Weight” on Tuesday, November 24. Jefferies maintained the shares of SCHN in report on Wednesday, September 16 with “Buy” rating.

Investors sentiment increased to 1.1 in Q3 2017. Its up 0.11, from 0.99 in 2017Q2. It is positive, as 15 investors sold Schnitzer Steel Industries, Inc. shares while 54 reduced holdings. 40 funds opened positions while 36 raised stakes. 23.36 million shares or 3.78% more from 22.51 million shares in 2017Q2 were reported. Guggenheim Cap Ltd reported 11,561 shares. Citigroup, New York-based fund reported 104,144 shares. Invesco Limited reported 0% of its portfolio in Schnitzer Steel Industries, Inc. (NASDAQ:SCHN). Credit Suisse Ag reported 31,862 shares. 4,500 were accumulated by Pacad Investment. Manufacturers Life Ins Com The accumulated 20,366 shares or 0% of the stock. Verition Fund Management Ltd Limited Liability Company has invested 0.04% of its portfolio in Schnitzer Steel Industries, Inc. (NASDAQ:SCHN). Focused Wealth Mngmt Inc reported 63 shares or 0% of all its holdings. Alliancebernstein Lp invested in 67,157 shares or 0% of the stock. Moreover, Hillcrest Asset Mngmt Ltd Liability Com has 1.02% invested in Schnitzer Steel Industries, Inc. (NASDAQ:SCHN) for 200,762 shares. National Bank Of Montreal Can stated it has 0% in Schnitzer Steel Industries, Inc. (NASDAQ:SCHN). Parametric Port Associate Ltd Liability Co holds 0% in Schnitzer Steel Industries, Inc. (NASDAQ:SCHN) or 64,847 shares. Moreover, Mark Sheptoff Fincl Planning Ltd Liability Corp has 0.27% invested in Schnitzer Steel Industries, Inc. (NASDAQ:SCHN). Paloma Ptnrs owns 8,552 shares or 0% of their US portfolio. Numeric Limited Liability Company, a Massachusetts-based fund reported 516,165 shares.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor biology. The company has market cap of $688.24 million. The Company’s lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. It currently has negative earnings. The firm is also developing a HIF portfolio of product candidates that include AKB-6899 for the treatment of anemia; and AKB-5169, a preclinical compound for the treatment for inflammatory bowel disease.

The stock decreased 1.49% or $0.22 during the last trading session, reaching $14.56. About 65,341 shares traded. Akebia Therapeutics, Inc. (NASDAQ:AKBA) has risen 76.80% since February 16, 2017 and is uptrending. It has outperformed by 60.10% the S&P500.

Since August 15, 2017, it had 0 buys, and 4 sales for $302,477 activity. Dahan Michel sold $27,457 worth of stock or 1,398 shares. Shares for $23,332 were sold by Nash Duane. $155,188 worth of Akebia Therapeutics, Inc. (NASDAQ:AKBA) was sold by Hadas Nicole R. on Monday, October 2.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: